

Regimen Reference Order – GYNE - olaparib

ARIA: GYNE – [olaparib]

Planned Course: Newly diagnosed:
Twice daily until disease progression or unacceptable toxicity up to 2 years
(1 cycle= 30 days)
OR
Relapsed platinum-sensitive:
Twice daily until disease progression or unacceptable toxicity
(1 cycle= 30 days)

Indication for Use: BRCA-Mutated Ovarian Cancer, Maintenance Therapy

Proceed with treatment if:

ANC equal to or greater than $1.2 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – GYNE - olaparib

Drug	Dose	CCMB Administration Guideline
olaparib	300 mg	Orally twice daily with or without food Swallow whole (Self-administered at home)
Tablet formulation: olaparib (Lynparza®) available dosage strengths: 100 mg, 150 mg tablets Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

All Cycles

- CBC and biochemistry as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
ondansetron	8 mg	Orally every 8 hours as needed for nausea and vomiting
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

INSTRUCTIONS FOR PATIENT

- Instruct patient to continue taking anti-emetic(s) at home
- olaparib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit or grapefruit juice
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on olaparib

ADDITIONAL INFORMATION

- olaparib can rarely cause pneumonitis
- olaparib can rarely cause secondary malignancy. Monitor for prolonged cytopenia
- olaparib is teratogenic. Women of childbearing potential should use effective contraception while on olaparib